Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 649

1.

Melanoma.

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S.

Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Review.

PMID:
30238891
2.

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment.

Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F.

Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018.

PMID:
30221038
3.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Sep 12. pii: S1470-2045(18)30497-2. doi: 10.1016/S1470-2045(18)30497-2. [Epub ahead of print]

PMID:
30219628
4.

Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.

Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, Nagore E, Kumar R.

Genes Chromosomes Cancer. 2018 Sep 11. doi: 10.1002/gcc.22669. [Epub ahead of print]

PMID:
30203894
5.

Informationssuche und Nutzung von Informationsquellen durch Melanompatienten deutscher Hautkrebszentren.

Brütting J, Bergmann M, Garzarolli M, Rauschenberg R, Weber C, Berking C, Tilgen W, Schadendorf D, Meier F; im Namen der NVKH-Unterstützergruppe.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1093-1102. doi: 10.1111/ddg.13630_g. No abstract available.

PMID:
30179323
6.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

PMID:
30150660
7.

Intraoperative use of LIGHTVISION: a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patients.

Teramoto Y, Nakamura Y, Asami Y, Matsuya T, Brinker TJ, Jansen P, Schulz A, Stoffels I, Klode J, Schadendorf D, Yamamoto A.

Eur J Dermatol. 2018 Aug 21. doi: 10.1684/ejd.2018.3308. [Epub ahead of print] No abstract available.

PMID:
30129521
8.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Aug 20:e12901. doi: 10.1111/ecc.12901. [Epub ahead of print]

PMID:
30126009
9.

Patient-reported outcomes with nivolumab in advanced solid cancers.

Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, Shaw JW.

Cancer Treat Rev. 2018 Aug 2;70:75-87. doi: 10.1016/j.ctrv.2018.08.001. [Epub ahead of print] Review.

10.

NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.

Pylaeva E, Harati MD, Spyra I, Bordbari S, Strachan S, Thakur BK, Höing B, Franklin C, Skokowa J, Welte K, Schadendorf D, Bankfalvi A, Brandau S, Lang S, Jablonska J.

Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31808. [Epub ahead of print]

PMID:
30121947
11.

A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic.

Brinker TJ, Brieske CM, Esser S, Klode J, Mons U, Batra A, Rüther T, Seeger W, Enk AH, von Kalle C, Berking C, Heppt MV, Gatzka MV, Bernardes-Souza B, Schlenk RF, Schadendorf D.

J Med Internet Res. 2018 Aug 15;20(8):e10976. doi: 10.2196/10976.

12.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Sep;101:236-243. doi: 10.1016/j.ejca.2018.06.034. Epub 2018 Aug 7.

13.

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma.

Dummer R, Michielin O, Nägeli MC, M Goldinger S, Campigotto F, Kriemler-Krahn U, Schmid H, Pedroncelli A, Micaletto S, Schadendorf D.

ESMO Open. 2018 Jul 23;3(5):e000388. doi: 10.1136/esmoopen-2018-000388. eCollection 2018.

14.

Information-seeking and use of information resources among melanoma patients of German skin cancer centers.

Brütting J, Bergmann M, Garzarolli M, Rauschenberg R, Weber C, Berking C, Tilgen W, Schadendorf D, Meier F; NVKH supporting group.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1093-1101. doi: 10.1111/ddg.13630. Epub 2018 Aug 9.

PMID:
30091517
15.

Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma.

Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC.

Clin Cancer Res. 2018 Jul 30. pii: clincanres.1184.2018. doi: 10.1158/1078-0432.CCR-18-1184. [Epub ahead of print]

PMID:
30061360
16.

Facial-Aging App Availability in Waiting Rooms as a Potential Opportunity for Skin Cancer Prevention.

Brinker TJ, Klode J, Esser S, Schadendorf D.

JAMA Dermatol. 2018 Sep 1;154(9):1085-1086. doi: 10.1001/jamadermatol.2018.1907. No abstract available.

PMID:
30046805
17.

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.

Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A.

J Natl Cancer Inst. 2018 Jun 1;110(6):677-681. doi: 10.1093/jnci/djx271.

PMID:
29917141
18.

Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.

Milsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M, Schadendorf D, Schilling B.

Eur J Cancer. 2018 Aug;99:58-65. doi: 10.1016/j.ejca.2018.05.012. Epub 2018 Jun 12.

PMID:
29906735
19.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.

Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M.

Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25.

20.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Jun 13. doi: 10.1158/1078-0432.CCR-18-1116. [Epub ahead of print]

PMID:
29898988
21.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.

Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D.

Clin Cancer Res. 2018 Sep 15;24(18):4494-4504. doi: 10.1158/1078-0432.CCR-18-0763. Epub 2018 Jun 11.

PMID:
29891723
22.

Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Schaarschmidt BM, Grueneisen J, Stebner V, Klode J, Stoffels I, Umutlu L, Schadendorf D, Heusch P, Antoch G, Pöppel TD.

Eur J Nucl Med Mol Imaging. 2018 Jun 6. doi: 10.1007/s00259-018-4061-9. [Epub ahead of print]

PMID:
29876618
23.

PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer.

de Semir D, Bezrookove V, Nosrati M, Dar AA, Wu C, Shen J, Rieken C, Venkatasubramanian M, Miller JR 3rd, Desprez PY, McAllister S, Soroceanu L, Debs RJ, Salomonis N, Schadendorf D, Cleaver JE, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5766-E5775. doi: 10.1073/pnas.1804779115. Epub 2018 Jun 4.

PMID:
29866840
24.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

PMID:
29863979
25.

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.

Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.

Eur J Cancer. 2018 Jul;98:10-16. doi: 10.1016/j.ejca.2018.04.010. Epub 2018 May 26.

PMID:
29843107
26.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC.

PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

27.

Unmet information needs of patients with melanoma in Germany.

Brütting J, Bergmann M, Garzarolli M, Rauschenberg R, Weber C, Berking C, Tilgen W, Schadendorf D, Meier F; on behalf of the NVKH supporting group.

Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464. [Epub ahead of print]

PMID:
29787460
28.

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Bezrookove V, Nosrati M, Miller JR 3rd, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M.

Clin Cancer Res. 2018 Sep 1;24(17):4119-4125. doi: 10.1158/1078-0432.CCR-18-0791. Epub 2018 May 18.

PMID:
29776954
29.

Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients.

Brütting J, Reinhardt L, Bergmann M, Schadendorf D, Weber C, Tilgen W, Berking C, Meier F; NVKH.

J Cancer Educ. 2018 May 7. doi: 10.1007/s13187-018-1369-x. [Epub ahead of print]

PMID:
29736794
30.

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pföhler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E; Dermatologic Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2018 Jun;96:34-43. doi: 10.1016/j.ejca.2018.01.075. Epub 2018 Apr 14.

PMID:
29665511
31.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

PMID:
29658430
32.

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.

Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, Neuberg D, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ.

Cell. 2018 Apr 19;173(3):624-633.e8. doi: 10.1016/j.cell.2018.03.026. Epub 2018 Apr 12.

PMID:
29656892
33.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
34.

NF1 mutations in conjunctival melanoma.

Scholz SL, Cosgarea I, Süßkind D, Murali R, Möller I, Reis H, Leonardelli S, Schilling B, Schimming T, Hadaschik E, Franklin C, Paschen A, Sucker A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Br J Cancer. 2018 May;118(9):1243-1247. doi: 10.1038/s41416-018-0046-5. Epub 2018 Mar 21.

PMID:
29559732
35.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
36.

A Skin Cancer Prevention Facial-Aging Mobile App for Secondary Schools in Brazil: Appearance-Focused Interventional Study.

Brinker TJ, Heckl M, Gatzka M, Heppt MV, Resende Rodrigues H, Schneider S, Sondermann W, de Almeida E Silva C, Kirchberger MC, Klode J, Enk AH, Knispel S, von Kalle C, Stoffels I, Schadendorf D, Nakamura Y, Esser S, Assis A, Bernardes-Souza B.

JMIR Mhealth Uhealth. 2018 Mar 9;6(3):e60. doi: 10.2196/mhealth.9794.

37.

A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised controlled trial.

Brinker TJ, Faria BL, Gatzka M, de Faria OM, Heppt MV, Kirchberger MC, Schadendorf D, Nakamura Y, Buslaff F, Lisboa OC, Oliveira ACC, Lino HA, Bernardes-Souza B.

BMJ Open. 2018 Mar 6;8(3):e018299. doi: 10.1136/bmjopen-2017-018299.

38.

Postsurgical Treatment of Split Skin Graft Donor Sites in Dermatological Departments.

Jansen P, Stoffels I, Klode J, Jockenhöfer F, Augustin M, Schadendorf D, Dissemond J.

Int J Low Extrem Wounds. 2018 Mar;17(1):22-29. doi: 10.1177/1534734617747685. Epub 2018 Mar 5.

PMID:
29502480
39.

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.

Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel JC.

Melanoma Res. 2018 Jun;28(3):204-210. doi: 10.1097/CMR.0000000000000435.

PMID:
29485532
40.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M.

Clin Chem. 2018 May;64(5):830-842. doi: 10.1373/clinchem.2017.281543. Epub 2018 Feb 26.

PMID:
29483107
41.

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.

Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29477665
42.

Dose-dependent toxicity of ipilimumab in metastatic melanoma.

Olischewsky A, De Schrijver S, Bankfalvi A, Wetter A, Zimmer L, Livingstone E, Schadendorf D, Ugurel S.

Eur J Cancer. 2018 May;95:104-108. doi: 10.1016/j.ejca.2018.01.088. Epub 2018 Feb 21. No abstract available.

PMID:
29477367
43.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

44.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

PMID:
29438368
45.

Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections-a cross-sectional, single-center study.

Storim J, Verheyen J, Wolff E, Wohlschlaeger J, Heintschel von Heinegg E, Schadendorf D, Esser S.

Sex Transm Infect. 2018 Feb 3. pii: sextrans-2017-053409. doi: 10.1136/sextrans-2017-053409. [Epub ahead of print]

PMID:
29431149
46.

[Information services for melanoma patients and awareness among those affected].

Brütting J, Bergmann M, Weber C, Berking C, Tilgen W, Schadendorf D, Meier F.

Hautarzt. 2018 Apr;69(4):335-339. doi: 10.1007/s00105-018-4130-9. German.

PMID:
29396641
47.

Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.

Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T.

Eur J Prev Cardiol. 2018 Mar;25(5):482-494. doi: 10.1177/2047487318755193. Epub 2018 Jan 29.

PMID:
29376753
48.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

49.

Reply to M. Horiguchi et al.

Schadendorf D, Jiang J, Kelleher T, Postow MA.

J Clin Oncol. 2018 Mar 1;36(7):721. doi: 10.1200/JCO.2017.76.5339. Epub 2018 Jan 16. No abstract available.

PMID:
29337639
50.

Sebaceous tumours: more than skin deep.

Jockenhöfer F, Schimming TT, Schaller J, Moege J, Livingstone E, Salva KA, Zimmer L, Schadendorf D, Rösch A.

Gut. 2017 Dec 15. pii: gutjnl-2017-315472. doi: 10.1136/gutjnl-2017-315472. [Epub ahead of print] No abstract available.

PMID:
29247065

Supplemental Content

Loading ...
Support Center